In Segment A, individuals will get various doses and schedules of oral ABBV-744 tablet to detect safe dosing regimen. More individuals is going to be enrolled at the recognized monotherapy dosign routine. In Section B, contributors will acquire oral ruxolitinib and ABBV-744 will be provided as "insert-on" therapy. In Segment https://simoncpzku.wizzardsblog.com/32023864/a-simple-key-for-abbv-744-brd4-inhibition-in-cancer-cell-lines-unveiled